文献速递血栓与止血

接受手术的血友病B患者中凝血因子IX的群体药代动力学

Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
PubMed 文献 · J Thromb Haemost · 2018-10-28

该研究基于118例接受255次手术的中重度血友病B患者,建立三室群体药代动力学模型描述围手术期凝血因子IX水平。典型34岁患者使用重组凝血因子IX时清除率为284 mL h⁻¹ 70 kg⁻¹,中央室分布容积5450 mL 70 kg⁻¹。围手术期药代动力学参数与预防治疗不同,模型或可用于手术期间药代动力学指导给药。

要点

  • 围手术期凝血因子IX药代动力学参数与预防治疗不同。
  • 重组凝血因子IX清除率284 mL h⁻¹ 70 kg⁻¹,中央室分布容积5450 mL 70 kg⁻¹。
  • 模型或可用于手术期间药代动力学指导给药。

核心结论

  • 围手术期血浆源性和重组凝血因子IX的药代动力学参数与预防治疗所报告的不同。
  • 所建立的模型或可用于手术期间药代动力学指导的凝血因子IX浓缩物给药。

研究设计与样本

  • 数据来自118例中度(28%)或重度(72%)血友病B患者,中位年龄40岁(范围0.2-90),体重79 kg(范围5.3-132),共接受255次手术。
  • 使用NONMEM非线性混合效应模型估计群体药代动力学参数。

主要发现

  • 围手术期凝血因子IX水平-时间曲线可用三室药代动力学模型充分描述。
  • 典型34岁使用重组凝血因子IX的患者:清除率284 mL h⁻¹ 70 kg⁻¹(个体间变异18%),中央室分布容积5450 mL 70 kg⁻¹(19%),Q2 110 mL h⁻¹ 70 kg⁻¹,V2 4800 mL 70 kg⁻¹,Q3 1610 mL h⁻¹ 70 kg⁻¹,V3 2040 mL 70 kg⁻¹。
  • 从0.2岁至34岁,清除率和中央室分布容积分别每年下降0.89%和1.15%。
  • 使用血浆源性凝血因子IX的患者较使用重组凝血因子IX的患者清除率低11%、中央室分布容积低17%。

临床怎么用

  • 作者认为所建立的模型或可用于手术期间药代动力学指导的凝血因子IX浓缩物给药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Essentials Factor IX (FIX) dosing using body weight frequently results in under and overdosing during surgery. We aimed to establish a population pharmacokinetic (PK) model describing the perioperative FIX levels. Population PK parameter values for clearance and V1 were 284 mL h-170 kg-1 and 5450 mL70 kg-1. Perioperative PK parameters differ from those during non-surgical prophylactic treatment. SUMMARY: Background Hemophilia B is a bleeding disorder characterized by a deficiency of coagulation factor IX (FIX). In the perioperative setting, patients receive FIX concentrates to ensure hemostasis. Although FIX is usually dosed according to bodyweight, under- and overdosing occurs frequently during surgery. Aim The objective was to quantify and explain the interpatient variability of perioperatively administered plasma-derived (pd) and recombinant (r) FIX concentrates. Methods Data were collected from 118 patients (median age, 40 years [range, 0.2-90]; weight, 79 kg [range, 5.3-132]) with moderate (28%) or severe hemophilia B (72%), undergoing 255 surgical procedures. Population pharmacokinetic (PK) parameters were estimated using nonlinear mixed-effect modeling in NONMEM. Results Measured perioperative FIX level vs. time profiles were adequately described using a three-compartment PK model. For a typical 34-year-old patient receiving rFIX, clearance (CL), intercompartmental clearance (Q2, Q3), distribution volume of the central compartment (V1) and peripheral compartments (V2, V3) plus interpatient variability (%CV) were: CL, 284 mL h-170 kg-1 (18%); V1, 5450 mL70 kg-1 (19%); Q2, 110 mL h-170 kg-1; V2, 4800 mL70 kg-1; Q3, 1610 mL h-170 kg-1; V3, 2040 mL70 kg-1. From 0.2 years, CL and V1 decreased 0.89% and 1.15% per year, respectively, until the age of 34 years. Patients receiving pdFIX exhibited a lower CL (11%) and V1 (17%) than patients receiving rFIX. Interpatient variability was successfully quantified and explained. Conclusions The estimated perioperative PK parameters of both pdFIX and rFIX are different from those reported for prophylactic treatment. The developed model may be used to apply PK-guided dosing of FIX concentrates during surgery.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Preijers T, Hazendonk HCAM, Liesner R, et al. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. J Thromb Haemost. 2018. PMID: 30394056. doi:10.1111/jth.14292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。